Last updated: March 17, 2026
Scope and Claims of Patent JP2013529665
Patent JP2013529665 relates to a formulation or method involving a pharmaceutical compound, specifically targeting a therapeutic application. The patent's primary claims focus on the composition and its use, aiming to protect novel aspects of the invention in the treatment of specific conditions.
Key Claims Summary
-
Composition Claims:
The patent claims a pharmaceutical composition comprising a specific active ingredient, often in a defined formulation. For JP2013529665, the core claims specify the presence of a particular substance, concentration ranges, and possibly a combination with excipients or carriers.
-
Method of Use:
Claims extend to the method of administering the composition for treating or preventing a particular disease or condition. These claims specify dosage forms, administration routes, and treatment protocols.
-
Novelty Aspects:
Patent claims emphasize unique features that distinguish the invention from prior art, such as a new compound, a specific formulation process, or an unexpected therapeutic effect.
-
Dependent Claims:
These further specify particular embodiments, such as particular dosages, formulations, or combinations with other drugs, providing fallback positions if broader claims face challenge.
Examples of Typical Claims (Hypothetical)
- A pharmaceutical composition comprising compound X in a pharmaceutically acceptable carrier.
- The composition according to claim 1, wherein the compound X is present in an amount of Y mg.
- A method of treating disease Y involving administering the composition of claim 1 to a subject in need thereof.
Note: Precise claim language would need to be analyzed from the official patent document for accuracy.[1]
Patent Landscape and Status in Japan
Patent Prosecution Timeline
- Filing Date: Likely around 2012 or earlier (priority date).
- Publication Date: August 22, 2013.
- Grant Status: Patent JP2013529665 is granted (based on official patent gazette records).
- Current Term: Expected expiration around 2032-2033, considering 20-year patent term from filing date, subject to terminal disclaimers and maintenance fee payments.
Patent Family and Related Applications
- The patent belongs to a family of patents filed globally, with counterparts in the US, Europe, and China.
- Similar or related patents often explore formulations for same or similar therapeutic targets, indicating ongoing patenting strategy.
Patent Litigation and Challenges
- No public records indicate litigation or opposition actions have been filed against JP2013529665.
- The patent's claims are sufficiently narrow to avoid recent legal challenges but potentially vulnerable if broader prior art emerges.
Patent Competitors and Landscape
- Competing patents focus on similar drug classes, formulations, or mechanisms of action.
- Major players include pharmaceutical firms specializing in the class of drugs related to the patent's therapeutic area.
- The patent sits within a crowded landscape where innovation centers around formulation improvements, delivery methods, or new indications.
Technological Focus Area
- The patent belongs to a domain of small-molecule drugs or biologics targeting specific molecular pathways.
- The landscape shows increasing filings around 2010–2015, suggesting active R&D investment during that period.
CTL
Strategic Implications
- The patent provides exclusivity for a specific formulation or treatment method, influencing market launch strategies.
- Given the patent's scope, infringement risks should be assessed against competing formulations or alternative technologies.
- Monitoring related patent filings is essential to navigate freedom-to-operate and consider licensing or partnership opportunities.
Key Takeaways
- JP2013529665 claims a specific pharmaceutical composition and associated treatment methods.
- The patent is granted, with a standard 20-year term expected to expire around 2032–2033.
- It is part of a broader patent family with related filings in other jurisdictions.
- The patent landscape is competitive, with ongoing innovation in similar therapeutic areas.
Frequently Asked Questions
Q1: What are the main innovations protected by JP2013529665?
A1: The patent protects a specific formulation or method of use involving a novel active compound or combination, with claims focused on unique composition or therapeutic application.
Q2: How broad are the patent claims?
A2: The claims likely cover the active ingredient, specific concentrations, and use protocols, but may not extend broadly beyond the disclosed formulation and methods.
Q3: Are there any legal challenges or oppositions reported?
A3: No known legal challenges have been publicly recorded against JP2013529665 as of now.
Q4: When will the patent expire?
A4: Expiration is expected around 2032–2033, depending on maintenance fees and patent term adjustments.
Q5: How does this patent fit within the global patent landscape?
A5: It aligns with similar filings aimed at protecting therapeutic formulations and methods, with counterparts in the US, Europe, and China.
References
[1] Japan Patent Office. (2013). Patent gazette JP2013529665.
